Combining genetic proxies of drug targets and time-to-event analyses from longitudinal observational data to identify target patient populations
Genetic proxies for well-known drugs corroborate findings from clinical trials in cardiovascular disease. Our results demonstrate a useful analytical approach that leverages genetic evidence from a large cohort with longitudinal outcomes data to effectively select patient populations where specific drug targets may be most effective.
Authors
- Tim Hoey
- Farshad Farshidfar (ORCID: https://orcid.org/0000-0003-3674-7336)
- Sylwia M. Figarska (ORCID: https://orcid.org/0000-0003-3601-1548)
- James R. Priest (ORCID: https://orcid.org/0000-0002-8349-4784)
- Whedy Wang
- Luke Zhang
- Whit Tingley
- Prachi Kulkarni
Institutions
- University of California San Diego (US)
- Stanford University (US)
Publication Details
- Journal
- BMC Cardiovascular Disorders
- Published
- 2025-05-07
- DOI
- https://doi.org/10.1186/s12872-025-04753-1
- Citations
- 2
- Primary Topic
- Genetic Associations and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 3.63